Abstract Background. In recent years, there has been a tendency towards minimally invasive surgical approaches to treat intraosseous defects. Emdogain is a gel composed of enamel matrix proteins derived from developing porcine (pig) embryos, used to promote the regeneration of periodontal tissues, including the cementum, periodontal ligament, and alveolar bone. Objective of the study. The aim of this study was to clinically evaluate the healing following treatment of intrabony defects with enamel matrix derivative. Material and Methods. Twenty (20) intrabony defects, of a probing depth of at least 6 mm, of 20 non-smoker patients (11 males, 9 females) were randomly treated with Prefgel and Emdogain (Test, n= 10) or only Prefgel (Control, n=10). The following clinical parameters were assessed at baseline and 6months after surgery: pocket depth (PD), bleeding on probing (BOP), gingival recession (GR) and clinical attachment level (CAL). Results. No statistically significant differences in any of the parameters were observed at baseline between groups. At 6months, Test group and Control group resulted in statistically significant clinical improvements from baseline (p< 0.05). Clinical measurements revealed that there was an equal reduction in bleeding on probing and probing depth between groups (p0.05). A greater statistically significant attachment gain and less gingival recession for the Test group when compared to Control group has been identified (p< 0.05). Conclusion. The results indicated that both treatments, in conjunction with a surgical approach, led to statistically significant clinical improvements compared to baseline. The present findings suggests that the application of enamel matrix derivative in periodontal intrabony defects may positively influence the clinical outcomes within a period of 6 months of follow-up. Keywords: Emdogain, infrabony defects, periodontal lesions, guided tissue regeneration.